PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

AZ announces US fast track designation for IL-5 inhibitor Fasenra

AstraZeneca’s IL-5 inhibitor Fasenra (benralizumab) has received a fast-track designation from the US Food and Drug Administration for the treatment of eosinoph...
Continue Reading →
News

AstraZeneca’s long-acting antibody combination treats and prevents COVID-19

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achi...
Continue Reading →
News

FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer

The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) for the treatment of patients with previously treated radioactive iodine-re...
Continue Reading →
News

FDA approval for Xywav for idiopathic hypersomnia in adults

Jazz Pharmaceutical’s Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults has been granted...
Continue Reading →
News

FDA approves Keytruda plus Lenvima for advanced kidney cancer

The US Food and Drug Administration (FDA) has approved a combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Eisai’s Lenvima (lenvatinib) for the fi...
Continue Reading →
News

US rejects AZ and FibroGen’s anaemia drug roxadustat

The US Food and Drug Administration (US) has handed AstraZeneca a complete response letter (CRL) regarding its anaemia drug roxadustat. AZ had submitted a new dru...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026